MariMed Q3 Revenue Hits $44.2M, Adjusted EBITDA $4.7M as Net Loss Widens
MRMD sits 66% above its 52-week low of $0.045 on elevated volume (1.9× avg).
Summary
MariMed posted record Q3 revenue of $44.2M, up from the record $41.9M in Q2, with adjusted EBITDA of $4.7M and an 11% adjusted EBITDA margin. Gross margin came in at 39% (40% adjusted), but the company still lost $3.5M on a net basis and $2.3M adjusted — a wider loss than Q2's $3.6M net loss on a smaller revenue base. The top line is growing, but profitability remains elusive at a micro-cap scale. This is the first hard look at Q3 numbers ahead of any formal release detail, and the quarter also brought positive operating cash flow. The reverse split approved October 29 (1-for-50 to 1-for-100) is still pending execution and will reset the share count and price.
At the time of this announcement, MRMD was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $30.1M. The 52-week trading range was $0.05 to $0.16. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.